Two-Day Fraction Gamma Knife Radiosurgery for Large Brain Metastasis
Open Access
- 1 September 2024
- journal article
- research article
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 67 (5) , 560-567
Abstract
Objective : We investigated how treating large brain metastasis (LBM) using 2-day fraction Gamma Knife radiosurgery (GKRS) affects tumor control and patient survival. A prescription dose of 10.3 Gy was applied for 2 consecutive days, with a biologically effective dose equivalent to a tumor single-fraction dose of 16.05 Gy and a brain single-fraction dose of 15.12 Gy.Methods : Between November 2017 and December 2021, 42 patients (mean age, 68.3 years; range, 50–84 years; male, 29 [69.1%]; female, 13 [30.9%]) with 44 tumors underwent 2-day fraction GKRS to treat large volume brain metastasis. The main cancer types were non-small cell lung cancer (n=16), small cell lung cancer (n=7), colorectal cancer (n=7), breast cancer (n=3), gastric cancer (n=2), and other cancers (n=7). Twenty-one patients (50.0%) had a single LBM, 19 (46.3%) had a single LBM and other metastases, and two had two (4.7%) large brain metastases. At the time of the 2-day fraction GKRS, the tumors had a mean volume of 23.1 mL (range, 12.5–67.4). On each day, radiation was administered at a dose of 10.3 Gy, mainly using a 50% isodose-line.Results : We obtained clinical and magnetic resonance imaging follow-up data for 34 patients (81%) with 35 tumors, who had undergone 2-day fraction GKRS. These patients did not experience acute or late radiation-induced complications during follow-up. The median and mean progression-free survival (PFS) periods were 188 and 194 days, respectively. The local control rates at 6, 9, and 12 months were 77%, 40%, and 34%, respectively. The prognostic factors related to PFS were prior radiotherapy (p=0.019) and lung cancer origin (p=0.041). Other factors such as tumor volumes, each isodose volumes, and peri-GKRS systemic treatment were not significantly related to PFS. The overall survival period of the 44 patients following repeat stereotactic radiosurgery (SRS) ranged from 15–878 days (median, 263±38 days; mean, 174±43 days) after the 2-day fraction GKRS. Eight patients (18.2%) were still alive.Conclusion : Considering the unsatisfactory tumor control, a higher prescription dose should be needed in this procedure as a salvage management. Moreover, in the treatment for LBM with fractionated SRS, using different isodoses and prescription doses at the treatment planning for LBMs should be important. However, this report might be a basic reference with the same fraction number and prescription dose in the treatment for LBMs with frame-based SRS.Keywords
This publication has 37 references indexed in Scilit:
- Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastasesJournal of Neuro-Oncology, 2015
- Stereotactic radiotherapy for large solitary brain metastasesCancer/Radiothérapie, 2014
- Fractionated Stereotactic Radiotherapy using CyberKnife for the Treatment of Large Brain Metastases: A Dose Escalation StudyClinical Oncology, 2014
- Fractionated stereotactic radiosurgery for patients with brain metastasesJournal of Neuro-Oncology, 2014
- Stereotactic radiosurgery in the treatment of brain metastases: The current evidenceCancer Treatment Reviews, 2014
- Local progression and pseudo progression after single fraction or fractionated stereotactic radiotherapy for large brain metastasesStrahlentherapie und Onkologie, 2012
- Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factorsJournal of Neuro-Oncology, 2012
- A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumorsJournal of Neuro-Oncology, 2012
- Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastasesJournal of Neuro-Oncology, 2012
- Dose fractionation, dose rate and iso-effect relationships for normal tissue responsesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1982